Poviztra 0.25 mg FlexTouch Injection 1.5 ml (Pen)

Poviztra 0.25 mg FlexTouch Injection Overview:

Poviztra 0.25 mg FlexTouch Injection contains semaglutide, a GLP-1 receptor agonist that helps regulate appetite and blood sugar levels. It works by enhancing insulin secretion, reducing excess glucagon, and slowing gastric emptying, which promotes a feeling of fullness and lowers calorie intake.

It is prescribed as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or those who are overweight with weight-related conditions such as Type 2 Diabetes, hypertension, or dyslipidaemia. In addition, it is indicated to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with established heart disease and excess weight.

Composition:

Each pre-filled pen contains 1 mg semaglutide in 1.5 mL solution (0.68 mg/mL).

Excipients: Disodium phosphate dihydrate 1.42 mg, Propylene glycerol 14.0 mg, Phenol 5.50 mg, Hydrochloric acid q.s. (for pH adjustment), Sodium Hydroxide q.s. (for pH adjustment), Water for injections to make 1.00 ml.

Uses and Benefits of Poviztra 0.25 mg FlexTouch Injection:

Poviztra 0.25 mg FlexTouch Injection is prescribed for the following conditions:

• Weight Management- Helps in weight loss for adults who are overweight or obese by increasing fullness, slowing stomach emptying, and reducing appetite.
• Cardiovascular Risk Reduction- Helps lower the risk of major cardiovascular events, including heart attack, stroke, or cardiovascular death, in adults with established heart disease who are overweight or obese.
• Weight Related Comorbid Condition- Used along with a reduced-calorie diet and increased physical activity in adults with obesity (BMI =30 kg/m²), or those who are overweight (BMI =27 kg/m²) with conditions such as hypertension, type 2 diabetes mellitus, or dyslipidaemia.
• Type 2 Diabetes Mellitus- Poviztra 0.25 mg FlexTouch Injection indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

How Poviztra 0.25 mg FlexTouch Injection works:

Poviztra 0.25 mg FlexTouch Injection contains semaglutide, a GLP-1 receptor agonist that replicates the action of the body’s natural incretin hormone involved in blood sugar and appetite regulation. It promotes insulin release when glucose levels are elevated and reduces glucagon secretion, thereby helping maintain balanced blood sugar levels. Additionally, it delays stomach emptying and influences appetite-regulating centers in the brain, leading to increased satiety, reduced hunger, and lower calorie intake.

Dosage of Poviztra 0.25 mg FlexTouch Injection:

• Usage Direction

Poviztra FlexTouch Injection is intended for subcutaneous use only and should be administered by an endocrinologists, internal medicine specialists, and cardiologists. It should be injected into areas of the body with a layer of fat just beneath the skin, such as the upper thigh, upper arm, or abdomen. Do not inject Poviztra  FlexTouch into a muscle (intramuscularly) or vein (intravenously). To reduce the risk of skin irritation, the injection site should be rotated each week. Do not attempt to self-administer this medication. Your endocrinologists, internal medicine specialists, and cardiologists will determine the appropriate dosage based on your medical condition and how you respond to treatment. Do not stop or alter the dose of Poviztra FlexTouch Injection without consulting your endocrinologists, internal medicine specialists, and cardiologists, as this may prevent you from achieving the desired result. Each injection pen is meant for single-person use only.

• Missed Dose

If a dose is missed and the next scheduled dose is more than 48 hours (2 days) away, the missed dose should be administered as soon as possible. If less than 48 hours (2 days) remain before the next dose, skip the missed dose and continue with the regular schedule. Patients using Poviztra should not take an extra dose to compensate for a missed dose.

• Overdose

In case of overdose, symptoms may include severe nausea, vomiting, and low blood sugar. Immediate medical attention is recommended. Supportive care and monitoring are usually required as there is no specific antidote for Poviztra FlexTouch Injection.

Contraindications of Poviztra 0.25 mg FlexTouch Injection:

Do not use Poviztra 0.25 mg FlexTouch Injection if you are allergic or hypersensitive to Semaglutide or any of its components. Additionally, Poviztra is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Poviztra should be avoided in individuals with a personal or family history of medullary thyroid carcinoma (MTC). It is also not recommended for patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic disorder that increases the risk of thyroid cancer.

Poviztra 0.25 mg FlexTouch Injection is also contraindicated in patients with known hypersensitivity (allergic reaction) to Semaglutide or any of its excipient ingredients. Additionally, Poviztra Injection should not be combined with other Semaglutide-containing products or with any other GLP-1 receptor agonist medicines.

Precautions & Warnings of Poviztra 0.25 mg FlexTouch Injection:

Before starting Poviztra, inform your endocrinologists, internal medicine specialists, and cardiologists about your medical history, especially if you have or have had pancreatic or kidney problems, or Type 2 Diabetes with a history of diabetic retinopathy. Also mention if you are scheduled for surgery or procedures involving anesthesia or deep sedation. Endocrinologists, internal medicine specialists, and cardiologists should evaluate the risk-benefit profile before initiating therapy.

Side Effects of Poviztra 0.25 mg FlexTouch Injection:

Poviztra 0.25 mg FlexTouch Injection should be used strictly under medical supervision, as it may cause significant adverse effects. The most common side effects include nausea, vomiting, diarrhea, constipation, and loss of appetite, which are usually mild and tend to improve as the body adjusts. However, if these symptoms continue, it is important to consult endocrinologists, internal medicine specialists, and cardiologists.

Other possible effects include dizziness, mild increased heart rate (tachycardia), headache, infections, and indigestion. Although severe & rare side effects may occur and require immediate medical attention. These include pancreatitis, acute kidney injury, worsening of diabetic retinopathy, gastroparesis (slowed or stopped stomach emptying), bowel obstruction, gallbladder-related complications such as gallstones, medullary thyroid cancer and bile duct blockage.

Use of Poviztra FlexTouch Injection may lead to noticeable physical changes as a result of rapid weight loss. One such effect is loss of facial fat, which can make the face appear hollow or sunken. This may be associated with features such as sunken eyes, increased wrinkles, sagging around the jawline (jowls), and changes in the appearance of the lips, cheeks, or chin.

Potential Health Complications of Poviztra 0.25 mg FlexTouch Injection:

Potential health complications of Poviztra 0.25 mg FlexTouch Injection may occur in some individuals despite its effectiveness. These include serious allergic reactions (anaphylaxis), which can present as shortness of breath, red rash, hives, abdominal pain, difficulty swallowing, chest tightness, or a sudden feeling of anxiety or doom.

Additionally, low blood sugar (hypoglycemia) may occur, particularly in patients with Type 2 Diabetes, with symptoms such as shaking, sweating, chills, dizziness, weakness, rapid heartbeat, intense hunger, difficulty concentrating, pale skin, or nausea.

Immediate medical attention is essential if any of these symptoms develop, and the medicine should always be used under proper medical supervision to minimize risks.

Safety Related Concerns of Poviztra 0.25 mg FlexTouch Injection:

• Pregnancy

Poviztra FlexTouch Injection is not recommended during pregnancy, as it may pose a risk of harm to the developing fetus, including potential abnormalities. Women who are pregnant or planning to conceive should avoid using this medication, and appropriate medical advice should be taken.

• Breastfeeding

Breastfeeding mothers are advised to avoid Poviztra 0.25 mg FlexTouch Injection as it may pass through breast milk and can cause side effects in breastfed babies.

• Alcohol

Alcohol may worsen gastrointestinal side effects like nausea and may affect blood sugar levels. Limiting alcohol intake is advisable.

• Driving & Using Machinery

Poviztra generally does not affect the ability to drive. However, caution is advised if you experience dizziness or low blood sugar, especially when used with other diabetes medicines.

• Food Interactions

There are no strict food restrictions, but following a reduced-calorie, balanced diet is essential for effectiveness. Fatty meals may worsen nausea.

• Drug Interactions

Poviztra may increase the risk of low blood sugar when used with insulin or insulin secretagogues (e.g., sulfonylureas), so dose adjustment may be needed. It also slows stomach emptying, which can affect how some oral medicines work. For example, levels of Levothyroxine may increase. Regular monitoring is advised when taking other medicines with Poviztra FlexTouch Injection.

Always inform your endocrinologists, internal medicine specialists, and cardiologists and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements, to avoid potential interactions.

Storage of Poviztra 0.25 mg FlexTouch Injection:

• Store in a refrigerator (2°C - 8°C). Do not freeze.
• After the first use of the pen, store below  30°C or in a refrigerator (2°C to 8°C). Do not freeze.
• Keep the pen cap on in order to protect from light.
• Discard pen 6 weeks after first use.
• Do not store the pen with a needle attached.
• Keep out of the sight and reach of children.
• Do not use Poviztra 0.25 mg FlexTouch Injection past its expiration date printed on the package. Dispose of expired or unused medications properly according to local guidelines or take them to a pharmacy take-back program.

Important Information:

• Read the package leaflet before use.
• People who are blind or have vision problems should not use this pen without help from a person trained to use the pen.

Related Blood Glucose Monitoring Systems:

To manage diabetes at home, discover our simple, reliable home-use Blood Glucose Monitoring systems with Test Strips. Check Out

Frequently Asked Questions:

Q. What is Poviztra 0.25 mg FlexTouch Injection used for?

A: Poviztra 0.25 mg FlexTouch Injection contains semaglutide, a GLP-1 receptor agonist that helps control appetite and blood sugar by increasing insulin, lowering glucagon, and slowing digestion. It is used with diet and exercise for weight management in obesity or overweight with conditions like Type 2 Diabetes, and reduces the risk of major cardiovascular events.

Q. How quickly does Poviztra FlexTouch Injection work?

A: Results vary from person to person depending on metabolism, lifestyle, and dose. Some people may notice reduced appetite within the first few weeks, while meaningful weight loss typically develops gradually over a few months. Consistent use along with diet and exercise is important for best results.

Q. Can Poviztra FlexTouch Injection reduce heart disease risk?

A: Yes, Poviztra FlexTouch Injection has been shown to reduce the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with existing heart disease and excess weight. This benefit is linked to its effects on weight reduction, blood sugar control, and overall metabolic health.

Q. Can I take Poviztra with other weight loss medicines?

A: It is generally not recommended to use Poviztra FlexTouch Injection with other weight loss medications unless advised by your doctor. Combining such treatments may increase the risk of side effects or complications. Always consult an endocrinologists, internal medicine specialists, and cardiologists before using any additional medicines for weight loss.

Q. Do I need a prescription for Poviztra FlexTouch Injection?

A: Yes, Poviztra is a prescription-only medicine. It can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists to ensure proper dosing, monitoring, and safety.

Reference:

1. Wegovy. Semaglutide Tablets 25 mg || Semaglutide Injection 1.7 mg/ 2.4 mg / 7.2 mg. Prescribing Information. Last Revised: March 2026. Accessed on: 14th April 2026.  Click Here

2. GLP-1 Drugs Use, Risks, and Regulation. Last Revised: 1st April 2026. Accessed on: 14th April 2026. >Click Here

3. Obesity: GLP-1 therapies. World Health Organization. Accessed on: 14th April 2026. Click Here

4. CDSCO. SL. No. 3 & 4. Accessed on: 14th April 2026. Click Here